{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:06:35Z","timestamp":1792652795688,"version":"4.5.0"},"reference-count":103,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,8,10]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec id=\"s1\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Review of efficacy and safety of Janus kinase (JAK) inhibition in immune-mediated inflammatory diseases (IMIDs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s2\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic literature research (SLR) of all publications on JAK inhibitors (JAKi) treatment published until March 2019 using MEDLINE, EMBASE and the Cochrane Library. Efficacy and safety were assessed in randomised controlled trials (RCTs), integrating long-term extension periods additionally for safety evaluation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s3\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>3454 abstracts were screened with 85 included in the final analysis (efficacy and RCT safety: n=72; safety only: n=13). Efficacy of RCTs investigating tofacitinib (TOFA, n=27), baricitinib (BARI, n=9), upadacitinib (UPA, n=14), filgotinib (FILGO, n=7), decernotinib (DEC, n=3) and peficitinib (PEF, n=7) was evaluated. Six head-to-head trials comparing JAKi with tumour necrosis factor inhibitors (TNFi) were included. Efficacy of JAKi was shown in rheumatoid arthritis (RA) for all agents, psoriatic arthritis (TOFA, FILGO), ankylosing spondylitis (TOFA, FILGO), systemic lupus erythematosus (BARI), chronic plaque psoriasis (TOFA, BARI, PEF), ulcerative colitis (TOFA, UPA), Crohn\u2019s disease (UPA, FILGO) and atopic dermatitis (TOFA, BARI, UPA). Safety analysis of 72 RCTs, one cohort study and 12 articles on long-term extension studies showed increased risks for infections, especially herpes zoster, serious infections and numerically higher rates of venous thromboembolic events. No increased malignancy rates or major adverse cardiac events were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s4\">\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>JAKi provide good efficacy compared to placebo (and to TNFi in RA and Pso) across various IMIDs with an acceptable safety profile. This SLR informed the task force on points to consider for the treatment of IMIDs with JAKi with the available evidence.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2020-001374","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T08:40:10Z","timestamp":1605256810000},"page":"e001374","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":54,"title":["Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct00550043","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6685-8873","authenticated-orcid":false,"given":"Andreas","family":"Kerschbaumer","sequence":"first","affiliation":[{"name":"Abteilung F\u00fcr Rheumatologie, Medizinische Universitat Wien Universitatsklinik Fur Innere Medizin III, Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[{"name":"Medicine 3, Division of Rheumatology, Medizinische Universitat Wien, Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-788X","authenticated-orcid":false,"given":"Peter","family":"Nash","sequence":"additional","affiliation":[{"name":"Griffith University School of Medicine, Gold Coast, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-7725","authenticated-orcid":false,"given":"Thomas","family":"Doerner","sequence":"additional","affiliation":[{"name":"Rheumatology, Charite Medical Faculty Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[{"name":"Hopital Cochin, Rheumatology, Universite Paris Descartes Faculte De Medecine Site Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[{"name":"Metroplex Clinical Research Center, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[{"name":"Sigmund Freud Private University Vienna, Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-8501","authenticated-orcid":false,"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK"},{"name":"University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Rheumatology, Keio Univ, School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[{"name":"Abteilung F\u00fcr Gastroenterologie, Medizinische Universitat Wien Universitatsklinik Fur Innere Medizin III, Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Winthrop","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-6354","authenticated-orcid":false,"given":"Maarten","family":"de Wit","sequence":"additional","affiliation":[{"name":"Patient Research Partner, EULAR, Zaltbommel, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Henning","family":"Boehncke","sequence":"additional","affiliation":[{"name":"Division of Dermatology and Venereology, Geneva University Hospitals, Geneve, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Falzon","sequence":"additional","affiliation":[{"name":"Center for Personalized Health, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"Desir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Rheumatology, LUMC, Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"key":"2025090312401005000_6.3.e001374.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24567"},{"key":"2025090312401005000_6.3.e001374.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"2025090312401005000_6.3.e001374.3","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/art.39808","article-title":"Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312401005000_6.3.e001374.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210104"},{"key":"2025090312401005000_6.3.e001374.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"2025090312401005000_6.3.e001374.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210322"},{"key":"2025090312401005000_6.3.e001374.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31363-1"},{"key":"2025090312401005000_6.3.e001374.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11168.x"},{"key":"2025090312401005000_6.3.e001374.9","article-title":"Effects of upadacitinib on atopic dermatitis signs, symptoms and patient-reported outcomes from a phase IIb randomized, placebo-controlled trial","volume":"179","author":"De Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025090312401005000_6.3.e001374.10","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2025090312401005000_6.3.e001374.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112168"},{"key":"2025090312401005000_6.3.e001374.12","first-page":"A3","article-title":"Safety and efficacy of upadacitinib (ABT-494), an oral JAK1 inhibitor, as induction therapy in patients with Crohn\u2019s disease: results from celest","volume":"5","author":"Sanborn","year":"2017","journal-title":"United Eur Gastroenterol J"},{"key":"2025090312401005000_6.3.e001374.13","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1093\/ecco-jcc\/jjx180.400","article-title":"Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn\u2019s disease: results from the CELEST study","volume":"12","author":"Panes","year":"2018","journal-title":"J Crohn\u2019s Colitis"},{"key":"2025090312401005000_6.3.e001374.14","doi-asserted-by":"crossref","unstructured":"Sandborn WJ , Feagan BG , Loftus EV Jr. , et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease. Gastroenterology 2020. doi: 10.1053\/j.gastro.2020.01.047","DOI":"10.1053\/j.gastro.2020.01.047"},{"key":"2025090312401005000_6.3.e001374.15","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol"},{"key":"2025090312401005000_6.3.e001374.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206350"},{"key":"2025090312401005000_6.3.e001374.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2025090312401005000_6.3.e001374.18","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316640910"},{"key":"2025090312401005000_6.3.e001374.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"2025090312401005000_6.3.e001374.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"2025090312401005000_6.3.e001374.21","first-page":"22","article-title":"Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic and safety outcomes from the 24-month phase 3 ORAL scan study","volume":"22","author":"van der Heijde","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312401005000_6.3.e001374.22","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312401005000_6.3.e001374.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.33383"},{"key":"2025090312401005000_6.3.e001374.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.33419"},{"key":"2025090312401005000_6.3.e001374.25","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"2025090312401005000_6.3.e001374.26","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.995875"},{"key":"2025090312401005000_6.3.e001374.27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/rheumatology\/key250","article-title":"Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study","volume":"58","author":"Tanaka","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312401005000_6.3.e001374.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"2025090312401005000_6.3.e001374.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"2025090312401005000_6.3.e001374.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"2025090312401005000_6.3.e001374.31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"2025090312401005000_6.3.e001374.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"2025090312401005000_6.3.e001374.33","unstructured":"Fleischmann R , Pangan AL , Mysler E , et al. A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate. 2018 ACR\/ARHP Annual Meeting Chicago, USA; 2018: Arthritis & Rheumatology; 2018."},{"key":"2025090312401005000_6.3.e001374.34","doi-asserted-by":"publisher","DOI":"10.1002\/art.41032"},{"key":"2025090312401005000_6.3.e001374.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62113-9"},{"key":"2025090312401005000_6.3.e001374.36","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312401005000_6.3.e001374.37","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150613"},{"key":"2025090312401005000_6.3.e001374.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"2025090312401005000_6.3.e001374.39","doi-asserted-by":"crossref","unstructured":"Hu J , Bao C , Li X , et al. Efficacy and safety of baricitinib in MTX-IR patients with rheumatoid arthritis: 52 week results from a phase 3 study (RA-balance). Annals of the rheumatic diseases Conference: annual European congress of rheumatology, EULAR 2018 Netherlands. 2018; 77 (Supplement2): 969\u2013970","DOI":"10.1136\/annrheumdis-2018-eular.1983"},{"key":"2025090312401005000_6.3.e001374.40","unstructured":"Yue Y , Hu J , Bao C , et al. Patient-reported outcomes from a phase 3 study (RA-BALANCE) of baricitinib versus placebo in rheumatoid arthritis. International Journal of Rheumatic Diseases Conference: 20th Asia Pacific League of Associations for Rheumatology Congress, APLAR 2018 Taiwan (republic of china). 2018; 21 (Supplement1): 40."},{"key":"2025090312401005000_6.3.e001374.41","doi-asserted-by":"crossref","unstructured":"Takeuchi T , Genovese MC , Haraoui B , et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis 2018. doi: 10.1136\/annrheumdis-2018-213271","DOI":"10.1136\/annrheumdis-2018-eular.2000"},{"key":"2025090312401005000_6.3.e001374.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213271"},{"key":"2025090312401005000_6.3.e001374.43","doi-asserted-by":"crossref","unstructured":"van Vollenhoven R , Takeuchi T , Pangan AL , et al. A phase 3, randomized, controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-na\u00efve patients with active rheumatoid arthritis - ACR meeting abstracts. 2018 ACR\/ARHP Annual Meeting Chicago, USA; 2018: Arthritis & Rheumatology; 2018.","DOI":"10.1093\/rheumatology\/kez106.058"},{"key":"2025090312401005000_6.3.e001374.44","doi-asserted-by":"crossref","unstructured":"Smolen J , Cohen S , Emery P , et al. Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate. Annals of the rheumatic diseases Conference: annual European congress of rheumatology, EULAR 2018, Netherlands. 2018; 77 (Supplement2): 67\u201368.","DOI":"10.1136\/annrheumdis-2018-eular.4237"},{"key":"2025090312401005000_6.3.e001374.45","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"2025090312401005000_6.3.e001374.46","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"2025090312401005000_6.3.e001374.47","doi-asserted-by":"crossref","unstructured":"Tanaka Y , Takeuchi T , Yamaoka K , et al. A phase 2b\/3 randomised, placebo-controlled, double-blind study of upadacitinib, a selective jak1 inhibitor, in Japanese patients with active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs. Annals of the rheumatic diseases Conference: annual European congress of rheumatology, EULAR 2018, Netherlands. 2018; 77 (Supplement2): 991\u2013992.","DOI":"10.1136\/annrheumdis-2018-eular.4302"},{"key":"2025090312401005000_6.3.e001374.48","doi-asserted-by":"crossref","unstructured":"Kameda H , Takeuchi T , Yamaoka K , et al. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study. Rheumatology (Oxford) 2020. doi: 10.1093\/rheumatology\/keaa084","DOI":"10.1093\/rheumatology\/keaa084"},{"key":"2025090312401005000_6.3.e001374.49","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/art.39801","article-title":"A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti: tumor necrosis factor therapy","volume":"68","author":"Kremer","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312401005000_6.3.e001374.50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"2025090312401005000_6.3.e001374.51","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210105"},{"key":"2025090312401005000_6.3.e001374.52","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/art.40186","article-title":"Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK-1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized phase IIA trials","volume":"69","author":"Vanhoutte","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312401005000_6.3.e001374.53","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.38949","article-title":"A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis","volume":"67","author":"Fleischmann","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090312401005000_6.3.e001374.54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39473","article-title":"VX-509 (Decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312401005000_6.3.e001374.55","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208901"},{"key":"2025090312401005000_6.3.e001374.56","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208279"},{"key":"2025090312401005000_6.3.e001374.57","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/art.40054","article-title":"Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312401005000_6.3.e001374.58","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.39955","article-title":"Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate","volume":"69","author":"Kivitz","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312401005000_6.3.e001374.59","unstructured":"Tanaka Y , Takeuchi T , Tanaka S , et al. Efficacy and safety of the novel oral janus kinase (JAK) inhibitor, peficitinib (ASP015K), in a phase 3, double-blind, placebo-controlled, randomized study of patients with RA who had an inadequate response to DMARDs. 2018 ACR\/ARHP Annual Meeting Chicago, USA; 2018: Arthritis & Rheumatology; 2018."},{"key":"2025090312401005000_6.3.e001374.60","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215163"},{"key":"2025090312401005000_6.3.e001374.61","unstructured":"Takeuchi T , Tanaka Y , Tanaka S , et al. Efficacy and safety of the novel oral Janus kinase (JAK) inhibitor, peficitinib (ASP015K), in a phase 3, double-blind, placebo-controlled, randomized study of patients with RA who had an inadequate response to methotrexate. 2018 ACR\/ARHP Annual Meeting Chicago, USA; 2018: Arthritis & Rheumatology; 2018."},{"key":"2025090312401005000_6.3.e001374.62","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215164"},{"key":"2025090312401005000_6.3.e001374.63","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090312401005000_6.3.e001374.64","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32483-8"},{"key":"2025090312401005000_6.3.e001374.65","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32463-2"},{"key":"2025090312401005000_6.3.e001374.66","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018"},{"key":"2025090312401005000_6.3.e001374.67","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J Dermatol Sci"},{"key":"2025090312401005000_6.3.e001374.68","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13551"},{"key":"2025090312401005000_6.3.e001374.69","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14403"},{"key":"2025090312401005000_6.3.e001374.70","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/09546634.2015.1115819","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis","volume":"27","author":"Bissonnette","year":"2016","journal-title":"J Dermatological Treat"},{"key":"2025090312401005000_6.3.e001374.71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"2025090312401005000_6.3.e001374.72","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"2025090312401005000_6.3.e001374.73","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/bjd.16014","article-title":"Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study","volume":"178","author":"Nakagawa","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025090312401005000_6.3.e001374.74","first-page":"1","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"1","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025090312401005000_6.3.e001374.75","first-page":"52","article-title":"Selective oral JAK3 and TYK2\/JAK1 kinase inhibitors both demonstrate significant hair-growth compared to placebo and improvement of hair-associated keratins in patients with moderate-to-severe alopecia areata","volume":"27","author":"Guttman-Yassky","year":"2018","journal-title":"Exp Dermatol"},{"key":"2025090312401005000_6.3.e001374.76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910"},{"key":"2025090312401005000_6.3.e001374.77","first-page":"A74","article-title":"Efficacy and safety of upadacitinib as an induction therapy for patients with moderately-to severely active ulcerative colitis: data from the phase 2b study u-achieve","volume":"6","author":"Sandborn","year":"2018","journal-title":"United Eur Gastroenterol J"},{"key":"2025090312401005000_6.3.e001374.78","doi-asserted-by":"crossref","unstructured":"Sandborn WJ , Ghosh S , Panes J , et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology 2020. doi: 10.1053\/j.gastro.2020.02.030","DOI":"10.1053\/j.gastro.2020.02.030"},{"key":"2025090312401005000_6.3.e001374.79","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/ecco-jcc\/jjy085","article-title":"Peficitinib, an oral Janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomised, phase 2 study","volume":"12","author":"Sands","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2025090312401005000_6.3.e001374.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.01.029"},{"key":"2025090312401005000_6.3.e001374.81","first-page":"16","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials","volume":"16","author":"Panes","year":"2017","journal-title":"Gut"},{"key":"2025090312401005000_6.3.e001374.82","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"2025090312401005000_6.3.e001374.83","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312401005000_6.3.e001374.84","unstructured":"FDA briefing document arthritis advisory committee meeting April 23, 2018. 2019. Available https:\/\/www.fda.gov\/media\/112372\/download (accessed 24 May 2020)"},{"key":"2025090312401005000_6.3.e001374.85","unstructured":"EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. 2019. Available https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots (accessed 24 May 2020)"},{"key":"2025090312401005000_6.3.e001374.86","unstructured":"Safety study of tofacitinib versus tumor necrosis factor (TNF) inhibitor in subjects with rheumatoid arthritis. 2020. Available https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02092467 (accessed 24 May 2020)"},{"key":"2025090312401005000_6.3.e001374.87","unstructured":"Highlights of prescribing information - Xeljanz (tofacitinib). 2019. Available https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf (accessed 24 May 2020)"},{"key":"2025090312401005000_6.3.e001374.88","unstructured":"Summary of product characteristics - Xeljanz (tofacitinib). 2020 (cited 24 May 2020); Available https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf"},{"key":"2025090312401005000_6.3.e001374.89","unstructured":"Summary of product characteristics - Olumiant (baricitinib). 2019 (cited 24 May 2020); Available https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-epar-product-information_en.pdf"},{"key":"2025090312401005000_6.3.e001374.90","unstructured":"Highlights of prescribing information - Olumiant (baricitinib). 2019. Available https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207924s000lbl.pdf (accessed 24 May 2020)"},{"key":"2025090312401005000_6.3.e001374.91","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457"},{"key":"2025090312401005000_6.3.e001374.92","first-page":"23","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"23","author":"Sandborn","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090312401005000_6.3.e001374.93","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjd.17149","article-title":"Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials","volume":"180","author":"Strober","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025090312401005000_6.3.e001374.94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.023"},{"key":"2025090312401005000_6.3.e001374.95","doi-asserted-by":"crossref","unstructured":"Winthrop KL , Melmed GY , Vermeire S , et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. American journal of gastroenterology conference: 82nd annual scientific meeting of the American College of Gastroenterology United states. 2017; 112 (Supplement 1):S327\u2013S328.","DOI":"10.14309\/00000434-201710001-00604"},{"key":"2025090312401005000_6.3.e001374.96","doi-asserted-by":"crossref","unstructured":"Winthrop KL , Melmed GY , Vermeire S , et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Journal of Crohn\u2019s and Colitis Conference: 13th congress of European Crohn\u2019s and Colitis Organisation, ECCO 2018 Austria. 2018; 12 (Supplement 1): S364.","DOI":"10.1093\/ecco-jcc\/jjx180.639"},{"key":"2025090312401005000_6.3.e001374.97","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312401005000_6.3.e001374.98","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2016.06.012","article-title":"Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis","volume":"75","author":"Wu","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2025090312401005000_6.3.e001374.99","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjx180.032","article-title":"The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme","volume":"12","author":"Sands","year":"2018","journal-title":"J Crohn\u2019s Colitis"},{"key":"2025090312401005000_6.3.e001374.100","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171361"},{"key":"2025090312401005000_6.3.e001374.101","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf"},{"key":"2025090312401005000_6.3.e001374.102","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2025090312401005000_6.3.e001374.103","doi-asserted-by":"crossref","unstructured":"Nash P , Kerschbaumer A , D\u00f6rner T , et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis 2020.doi: 10.1136\/annrheumdis-2020-218398","DOI":"10.1136\/annrheumdis-2020-218398"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:40:28Z","timestamp":1756928428000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":103,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,11,13]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/rmdopen-2020-001374"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001374","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}